[Neuroblastoma in children]

Area of Science:

• Pediatric Oncology
• Cancer Biology
• Tumor Pathology

Background:

• Neuroblastomas exhibit diverse clinical presentations, from benign to aggressive malignant forms.
• Over 50% of neuroblastomas are high-risk, characterized by frequent recurrence.
• Current survival rates for high-risk neuroblastoma remain below 40% despite intensive multidisciplinary treatments.

Purpose of the Study:

• To highlight the critical need for a comprehensive re-evaluation of the current medical approach to neuroblastoma.
• To emphasize the importance of refining diagnostic and staging methods.
• To underscore the necessity of advancing our understanding of tumor biology and pathology for improved therapeutic strategies.

Main Methods:

• Analysis of extensive international study data spanning from the early 1970s.
• Review of clinical presentations, diagnostic criteria, and staging protocols.
• Examination of therapeutic outcomes and recurrence rates in high-risk neuroblastoma cases.

Main Results:

• Data indicates significant heterogeneity in neuroblastoma clinical behavior.
• High-risk neuroblastomas demonstrate a persistent challenge with high recurrence rates.
• Existing therapeutic strategies have not sufficiently improved survival for high-risk pediatric neuroblastoma.

Conclusions:

• A fundamental reassessment of neuroblastoma diagnosis and staging is urgently required.
• Deeper insights into neuroblastoma tumor biology and pathology are essential for therapeutic advancements.
• International collaborative efforts are necessary to re-evaluate and optimize treatment planning for improved patient outcomes.